Clinical Trials Logo

Leiomyosarcoma clinical trials

View clinical trials related to Leiomyosarcoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06308419 Not yet recruiting - Leiomyosarcoma Clinical Trials

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Start date: July 31, 2024
Phase: Phase 1
Study type: Interventional

To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.

NCT ID: NCT06277154 Not yet recruiting - Leiomyosarcoma Clinical Trials

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Start date: February 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.

NCT ID: NCT05548179 Not yet recruiting - Leiomyosarcoma Clinical Trials

Exploring Clinical Trial Experiences of People With Leiomyosarcoma

Start date: October 2023
Phase:
Study type: Observational

Clinical study participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this study so that it may collect a variety of data about leiomyosarcoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. People with leiomyosarcoma who are invited to take part in medical research will benefit from the analysis of the data.

NCT ID: NCT05515068 Not yet recruiting - Osteosarcoma Clinical Trials

Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas

COSS-Registry
Start date: September 2022
Phase:
Study type: Observational [Patient Registry]

The Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) is a non-interventional, multicentric, international, clinical and epidemiologic patient registry. The COSS-Registry collects key data on osteosarcomas or biologically related bone sarcomas. With that data collection we want to gain new scientific insights and results about this tumor disease, prognosis, surveillance and long-term effects. Besides the data collection we would also like to foster the collection of biomaterial (tumor specimen and blood samples) for scientific research. The stored material will be used to perform cell and molecular biological analyses to identify the causes of osteosarcoma, the prognosis and possible new treatment options. As a starting point the donated biomaterial of registered patients will be analyzed firstly for the presence of a tumor predisposition by germline mutations. In case of detected genetic variations that are related to the tumor disease and which may affect the patient's health and follow-up care (because of the potentially increased risk of developing other malignant tumors), affected patients will be informed and referred to genetic counseling. Registry patients will be asked at the time of diagnosis if they wish to be informed about germline variants detected as part of the study procedures.